Marvelon (Desogestrel, Ethinylestradiol)

Desogestrel/Ethinylestradiol, the active ingredients in Marvelon, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH USA supplies Marvelon as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Marvelon, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy.

- Prevention of pregnancy: provides reliable hormonal contraception for women of reproductive age. - Contraception: offers a daily oral method to inhibit ovulation and prevent fertilisation. - Menstrual cycle regulation: can reduce irregular bleeding and dysmenorrhoea in users.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: occasional tension‑type headaches. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional fluctuations. - Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein clot formation. - Arterial thrombosis: stroke or myocardial infarction risk. - Hypertension: new or worsening high blood pressure. - Liver disorders: cholestatic jaundice or hepatic adenoma. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Major depression or suicidal thoughts: significant mood disturbances.

Before prescribing Marvelon, clinicians should evaluate individual risk factors and counsel patients on safe use. - Assess thrombotic risk: review personal and family history of clotting disorders. - Screen for hypertension: measure blood pressure regularly. - Evaluate liver function: consider baseline liver tests in patients with hepatic disease. - Counsel on smoking: advise cessation, especially in women over 35. - Review medication history: identify drugs that may reduce contraceptive efficacy. - Store at room temperature: keep in the original pack, protect from moisture and heat.

Marvelon may interact with several medicines that alter hormone metabolism or affect clotting risk.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): markedly reduce contraceptive effectiveness. - Rifampicin or other strong CYP3A4 inducers: may lead to breakthrough ovulation. - Certain antiretrovirals (e.g., efavirenz): decrease plasma hormone levels.

Moderate Interactions (Monitor Closely): - Antibiotics such as tetracycline or metronidazole: slight reduction in hormone concentrations. - Antifungal agents (e.g., ketoconazole, itraconazole): may increase hormone levels, raising side‑effect risk. - St John’s wort: herbal inducer that can lower contraceptive efficacy.